GlassScriptPhysician profile
Darla Norris
NPI 1083295117
$11,207.38
in general payments reported to CMS, 2019-2025
50 companies · $4,000 in 2025
The $4,000 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $560 · 2023: $3,149 · 2024: $3,498 · 2025: $4,000.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,468.87 |
| Education | $178.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,031.51 | 2022-2025 | Saphnelo, Fasenra, Bevespi Aerosphere |
| Genzyme Corporation | $1,766.58 | 2022-2025 | |
| Abbvie INC. | $691.89 | 2023-2025 | |
| Corium, LLC | $557.29 | 2023-2025 | Azstarys |
| Regeneron Healthcare Solutions, INC. | $532.53 | 2022-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $451.40 | 2023-2025 | Hyqvia, Cuvitru, Glassia |
| Glaxosmithkline, LLC. | $434.87 | 2023-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Optinose US, INC. | $271.48 | 2022-2025 | |
| Ucb, INC. | $250.35 | 2025 | Bimzelx |
| Verona Pharma, INC. | $239.89 | 2025 | Ohtuvayre |
| Blueprint Medicines Corporation | $228.81 | 2023-2025 | Ayvakit |
| Csl Behring | $209.67 | 2023-2025 | Hizentra, Haegarda |
| Electromed, INC. | $202.90 | 2022-2024 | Smartvest |
| Paratek Pharmaceuticals, INC. | $193.40 | 2024-2025 | Nuzyra, Xhance |
| Horizon Therapeutics Plc | $184.53 | 2022-2023 | Krystexxa |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $169.98 | 2025 | |
| Vanda Pharmaceuticals INC. | $169.44 | 2025 | Fanapt |
| Ars Pharmaceuticals Operations, INC. | $169.43 | 2025 | Neffy |
| Pharming Healthcare, INC. | $158.00 | 2023-2025 | Ruconest |
| Novartis Pharmaceuticals Corporation | $141.10 | 2023-2025 | |
| Genentech USA, INC. | $128.07 | 2023 | Xolair, Actemra |
| Lilly USA, LLC | $110.64 | 2024-2025 | Ebglyss, Zepbound, Mounjaro |
| Amgen INC. | $100.60 | 2022-2025 | Tezspire |
| Pfizer INC. | $84.39 | 2024-2025 | |
| Alk-Abello, INC | $54.10 | 2022-2023 | Ragwitek, Odactra, Grastek |
| Kaleo, INC. | $54.06 | 2022-2023 | Auvi-Q |
| Fresenius Kabi USA, LLC | $46.58 | 2023-2024 | Idacio |
| Novo Nordisk INC | $46.55 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $45.77 | 2024-2025 | Caplyta |
| Idorsia Pharmaceuticals US INC | $35.94 | 2023 | Quviviq |
| Organon LLC | $34.71 | 2023-2025 | Nexplanon |
| Tersera Therapeutics LLC | $33.91 | 2023 | Quzyttir |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.20 | 2023 | Xifaxan, Trulance |
| Philips North America LLC | $32.51 | 2023-2025 | Vest Therapy Und |
| Merck Sharp & Dohme LLC | $28.12 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.85 | 2024 | Ofev |
| Baxter Healthcare | $26.11 | 2025 | Hillrom - Monarch Airway Clearance System |
| Lundbeck LLC | $24.80 | 2025 | Rexulti |
| Aimmune Therapeutics, INC. | $22.95 | 2025 | Zenpep |
| Nestle Healthcare Nutrition INC. | $22.29 | 2022 | |
| Ani Pharmaceuticals, INC. | $21.10 | 2025 | Purified Cortrophin Gel |
| Pharmacosmos Therapeutics INC. | $19.72 | 2023 | Monoferric |
| Viatris Specialty LLC | $19.57 | 2025 | Yupelri |
| Octapharma USA, INC. | $17.00 | 2023 | Octagam Immune Globulin (Human) |
| Astellas Pharma US INC | $15.59 | 2024 | Veozah |
| Tonix Medicines, INC. | $14.34 | 2025 | Tonmya |
| Chiesi USA, INC. | $14.17 | 2023 | Bronchitol |
| Neurelis, INC. | $13.58 | 2023 | Valtoco |
| Gilead Sciences, INC. | $13.20 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $11.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darla Norris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.